Medpace Holdings, Inc. (MEDP)

About Medpace Holdings, Inc.

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

MEDP passes 1 of our 30 screens today

Each screen prints the exact criteria it used, and the circumstances in which it is wrong.

Smart money ownership

18 of the funds we track reported a position in their latest SEC 13F filing. Largest first:

• Cliff Asness, AQR CAPITAL MANAGEMENT LLC$633.60M · 0.3% of book
• Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$242.34M · 0.4% of book
• Baillie Gifford, BAILLIE GIFFORD & CO$241.63M · 0.3% of book
• D. E. Shaw, D. E. Shaw & Co., Inc.$207.73M · 0.1% of book
• Arrowstreet Capital, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP$190.04M · 0.1% of book

A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.

Common questions